Abstract:Importance: Community-acquired pneumonia (CAP) results in approximately 1.4 million emergency department visits, 740 000 hospitalizations, and 41 000 deaths in the US annually. Observations: Community-acquired pneumonia can be diagnosed in a patient with 2 or more signs (eg, temperature >38 °C or ≤36 °C; leukocyte count <4000/μL or >10 000/μL) or symptoms (eg, new or increased cough or dyspnea) of pneumonia in conjunction with consistent radiographic findings (eg, air space density) without an alternative explanation. Up to 10% of patients with CAP are hospitalized; of those, up to 1 in 5 require intensive care. Older adults (≥65 years) and those with underlying lung disease, smoking, or immune suppression are at highest risk for CAP and complications of CAP, including sepsis, acute respiratory distress syndrome, and death. Only 38% of patients hospitalized with CAP have a pathogen identified. Of those patients, up to 40% have viruses identified as the likely cause of CAP, with Streptococcus pneumoniae identified in approximately 15% of patients with an identified etiology of the pneumonia. All patients with CAP should be tested for COVID-19 and influenza when these viruses are common in the community because their diagnosis may affect treatment (eg, antiviral therapy) and infection prevention strategies. If test results for influenza and COVID-19 are negative or when the pathogens are not likely etiologies, patients can be treated empirically to cover the most likely bacterial pathogens. When selecting empirical antibacterial therapy, clinicians should consider disease severity and evaluate the likelihood of a bacterial infection-or resistant infection-and risk of harm from overuse of antibacterial drugs. Hospitalized patients without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days. Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality. Conclusions: Community-acquired pneumonia is common and may result in sepsis, acute respiratory distress syndrome, or death. First-line therapy varies by disease severity and etiology. Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days.

Hypoalbuminemia and Community-Acquired Pneumonia: A Dangerous Pro-Thrombotic Liaison

Hypoalbuminemia as predictor of thrombotic events in patients with community-acquired pneumonia

The Risk of Thrombosis after Acute-Covid-19 Infection

Long-Term Outcomes in Severe Community-Acquired Pneumonia

COVID-19 patients with acute pulmonary embolism have a higher mortality risk: systematic review and meta-analysis based on Italian cohorts.

Age-adjusted D-Dimer Cut-off Levels to Exclude Venous Thromboembolism in COVID-19 Patients

[Incidence of Acute Pulmonary Embolism in Hospitalized COVID-19 Italian Patients. A Pooled Meta-Analysis].

P279 MORTALITY RISK DUE TO ACUTE PULMONARY EMBOLISM IN COVID–19 PATIENTS: META–ANALYSIS BASED ON ITALIAN COHORTS

Pneumonia is Associated with Increased Mortality in Hospitalized COPD Patients: A Systematic Review and Meta-Analysis

The Global Burden of Community-Acquired Pneumonia in Adults, Encompassing Invasive Pneumococcal Disease and the Prevalence of Its Associated Cardiovascular Events, with a Focus on Pneumolysin and Macrolide Antibiotics in Pathogenesis and Therapy

Community-Acquired Pneumonia: A Review

An Investigation of Mortality Associated With Comorbid Pneumonia and Thrombocytopenia in a Rural Southwest Missouri Hospital System

Clinical analysis of nosocomial pneumonia after acute stroke

Burden of Community-Acquired Pneumonia and Unmet Clinical Needs

Prognostic Significance of Thrombocytopenia and Mean Platelet Volume in COPD Patients with Acute Exacerbations in ICU Settings

Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia.

Anemia, hypoalbuminemia, and elevated troponin levels as risk factors for respiratory failure in patients with severe exacerbations of chronic obstructive pulmonary disease requiring invasive mechanical ventilation

Severe Community-Acquired Pneumonia in Immunocompromised Patients

An Underestimated but Clinically Relevant Problem

Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: a systematic literature review

Community-acquired pneumonia: The importance of the early detection of drug-resistant organisms